Cat. No. 2489
Alternative Name: trans-C 75
Chemical Name: (2R*,3S*)-Tetrahydro-4-methylene-2-
Biological ActivitySynthetic inhibitor of fatty acid synthase (FASN); inhibits fatty acid synthesis in vitro and in vivo. Displays anorectic effects. Induces apoptosis in MCF-7 xenografts and exhibits anti-tumor activity.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Takahashi et al (2004) The anorexigenic fatty acid synthase inhibitor, C45, is a nonspecific neuronal activator. Endocrinology 145 184. PMID: 14512433.
Thupari et al (2004) Chronic C75 treatment of diet-induced obese mice increases fat oxidation and reduces food intake to reduce adipose mass. Am.J.Physiol.Endocrinol.Metab. 287 97.
Zhou et al (2003) Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res. 63 7330. PMID: 14612531.
Kuhajda et al (2000) Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc.Natl.Acad.Sci. 97 3450.
If you know of a relevant reference for C 75 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses C 75 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: C 75, supplier, trans-C75, transC75, C75, fatty, acid, synthase, inhibitor, enzyme, FASanorectic, anorexigenic, neuronal, activator, inhibits, inhibitors, fat, obese, apoptosis, anti-tumor, FASN, Tocris Bioscience, Fatty Acid Synthase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Highly potent and SAM-competitive EZH2 inhibitorGSK 591 dihydrochloride
Potent and selective PRMT5 inhibitorTP 064
Potent and selective PRMT 4 inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.